Hong Kong stock unusual movement | Rongchang Bio (09995.HK) surged over 7% Taitoxipu intends to include in priority review category, achieving Phase III research A stage main endpoint in the treatment of IgA nephropathy

According to the Securities Times app, Rongchang Biotechnology (09995.HK) has risen by more than 7%, as of the time of reporting, it has increased by 7.25% to 109.4 Hong Kong dollars, with a turnover of 3.57 billion Hong Kong dollars.